NASDAQ:CPIX - Nasdaq - US2307701092 - Common Stock - Currency: USD
5.31
-0.64 (-10.76%)
The current stock price of CPIX is 5.31 USD. In the past month the price increased by 112.4%. In the past year, price increased by 148.13%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 27.53 | 390.99B | ||
JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
PFE | PFIZER INC | 8.46 | 149.04B | ||
SNY | SANOFI-ADR | 13.62 | 136.54B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
GSK | GSK PLC-SPON ADR | 7.81 | 74.77B | ||
ZTS | ZOETIS INC | 27.1 | 72.39B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which focuses on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The company is headquartered in Nashville, Tennessee and currently employs 91 full-time employees. The company went IPO on 2009-08-11. The firm is focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. Its portfolio of brands includes Acetadote injection, for the treatment of acetaminophen poisoning; Caldolor injection, for the treatment of pain and fever, Kristalose for oral solution, a prescription laxative, for the treatment of constipation, and Omeclamox-Pak, oral, for the treatment of Helicobacter pylori infection and related duodenal ulcer disease. Its brands also include Sancuso transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia, and Vibativ injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia.
CUMBERLAND PHARMACEUTICALS
2525 W End Ave Ste 950
Nashville TENNESSEE 37203 US
CEO: A. J. Kazimi
Employees: 91
Company Website: https://www.cumberlandpharma.com/
Investor Relations: http://investor.shareholder.com/cpix/
Phone: 16152550068
The current stock price of CPIX is 5.31 USD. The price decreased by -10.76% in the last trading session.
The exchange symbol of CUMBERLAND PHARMACEUTICALS is CPIX and it is listed on the Nasdaq exchange.
CPIX stock is listed on the Nasdaq exchange.
CUMBERLAND PHARMACEUTICALS (CPIX) has a market capitalization of 74.55M USD. This makes CPIX a Micro Cap stock.
CUMBERLAND PHARMACEUTICALS (CPIX) currently has 91 employees.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CPIX does not pay a dividend.
CUMBERLAND PHARMACEUTICALS (CPIX) will report earnings on 2025-03-11.
CUMBERLAND PHARMACEUTICALS (CPIX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.17).
The outstanding short interest for CUMBERLAND PHARMACEUTICALS (CPIX) is 2.44% of its float. Check the ownership tab for more information on the CPIX short interest.
ChartMill assigns a technical rating of 9 / 10 to CPIX. When comparing the yearly performance of all stocks, CPIX is one of the better performing stocks in the market, outperforming 99.27% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to CPIX. CPIX may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months CPIX reported a non-GAAP Earnings per Share(EPS) of -0.17. The EPS decreased by -170.83% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -14.16% | ||
ROE | -43.87% | ||
Debt/Equity | 0.41 |
ChartMill assigns a Buy % Consensus number of 43% to CPIX. The Buy consensus is the average rating of analysts ratings from 6 analysts.